全文获取类型
收费全文 | 64080篇 |
免费 | 4359篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 593篇 |
儿科学 | 2487篇 |
妇产科学 | 1706篇 |
基础医学 | 8314篇 |
口腔科学 | 663篇 |
临床医学 | 9681篇 |
内科学 | 11134篇 |
皮肤病学 | 937篇 |
神经病学 | 5913篇 |
特种医学 | 1437篇 |
外科学 | 5717篇 |
综合类 | 717篇 |
一般理论 | 115篇 |
预防医学 | 8615篇 |
眼科学 | 876篇 |
药学 | 4163篇 |
中国医学 | 68篇 |
肿瘤学 | 5424篇 |
出版年
2023年 | 316篇 |
2022年 | 481篇 |
2021年 | 1133篇 |
2020年 | 767篇 |
2019年 | 1193篇 |
2018年 | 1340篇 |
2017年 | 1089篇 |
2016年 | 1163篇 |
2015年 | 1361篇 |
2014年 | 1889篇 |
2013年 | 3007篇 |
2012年 | 4318篇 |
2011年 | 4655篇 |
2010年 | 2587篇 |
2009年 | 2356篇 |
2008年 | 4221篇 |
2007年 | 4467篇 |
2006年 | 4316篇 |
2005年 | 4464篇 |
2004年 | 4239篇 |
2003年 | 3989篇 |
2002年 | 3656篇 |
2001年 | 729篇 |
2000年 | 630篇 |
1999年 | 729篇 |
1998年 | 780篇 |
1997年 | 710篇 |
1996年 | 568篇 |
1995年 | 559篇 |
1994年 | 505篇 |
1993年 | 407篇 |
1992年 | 455篇 |
1991年 | 428篇 |
1990年 | 362篇 |
1989年 | 361篇 |
1988年 | 353篇 |
1987年 | 306篇 |
1986年 | 318篇 |
1985年 | 303篇 |
1984年 | 295篇 |
1983年 | 259篇 |
1982年 | 279篇 |
1981年 | 278篇 |
1980年 | 201篇 |
1979年 | 174篇 |
1978年 | 199篇 |
1977年 | 130篇 |
1976年 | 135篇 |
1974年 | 160篇 |
1973年 | 117篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
72.
Tugba Yavuzsen Mellar P Davis Declan Walsh Susan LeGrand Ruth Lagman 《Journal of clinical oncology》2005,23(33):8500-8511
PURPOSE: We systematically assessed the efficacy and safety of appetite stimulants in the management of cancer-related anorexia. Literature databases were searched for randomized controlled trials of appetite stimulants in the treatment of cancer anorexia. MATERIALS AND METHODS: Studies were graded according to quality. Fifty-five studies met inclusion criteria. RESULTS: Only two drugs have evidence to support their use for anorexia (progestins and corticosteroids). There is strong evidence against the use of hydrazine sulfate. The outcomes of these trials have been mixed and patient population heterogeneous. CONCLUSION: The optimal dose, time to start, and duration of treatment for many appetite stimulants for cancer anorexia is still unknown. A more systematic approach to research methodology with universal outcome measure and prospective randomized studies are need. Combination regimens are needed but this cannot at the present time be supported by the data presented. 相似文献
73.
Summary DNA flow cytometry was used to examine the effects of five chemotherapeutic agents, vinblastine, cisplatinum, 5-fluorouracil, cyclophosphamide and Adriamycin, on mouse testes. Alterations in the haploid (1C), diploid (2C) and tetraploid (4C) cell compartments were assessed at 11, 29 and 56 days after giving mice a single intraperitoneal injection of each agent. Analysis of the histograms proved to be a rapid and reproducible method of monitoring injury in this animal model. Because this procedure can detect subtle testicular injuries, it is predicted that DNA histograms obtained from fine needle aspirates will gain increasing acceptance in the management of the oligo- and azoospermic patient. 相似文献
74.
Studies were carried out to investigate the metabolism of senecionine by human liver microsomes and the role of human cytochrome P450IIIA4 in this process. Human liver microsomes metabolized senecionine to two major products, (+/-)-6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) and senecionine N-oxide. The rates of product formation (DHP and senecionine N-oxide) varied widely with the microsomal samples tested. There was a 30-fold difference in DHP formation and a 25-fold difference in N-oxidation between the poorest metabolizer and the highest metabolizer of senecionine. The conversion of senecionine to DHP and senecionine N-oxide in human liver microsomes was markedly inhibited by the mechanism-based inactivators of P450IIIA4, gestodene and triacetyloleandomycin. Anti-P450IIIA4 IgG, at a concentration of 1 mg/nmol of P450, was found to inhibit completely the formation of DHP and senecionine N-oxide in human liver microsomes (HL101) having low activity toward senecionine. At 5 mg IgG/nmol P450, anti-P450IIIA4 inhibited 90 and 84% respectively of the formation of DHP and senecionine N-oxide in liver microsomes (HL110) with the highest activity toward senecionine. The formation of DHP or senecionine N-oxide was highly correlated with the amount of P450IIIA4 measured in the microsomes using polyclonal anti-P450IIIA4 IgG. The rate of DHP production also had a strong correlation with the rate of senecionine N-oxide formation (r = 0.999) and with the rate of nifedipine oxidation (r = 0.998). Our present studies provide evidence that P450IIIA4 is the major enzyme catalyzing the bioactivation (DHP formation) and detoxication (senecionine N-oxide formation) of senecionine in human liver. 相似文献
75.
76.
Mats Bergstrom Azita Monazzam Pasha Razifar Susan Ide Raymond Josephsson Bengt Langstrom 《Journal of nuclear medicine》2008,49(7):1204-1210
For a PET agent to be successful as a biomarker in early clinical trials of new anticancer agents, some conditions need to be fulfilled: the selected tracer should show a response that is related to the antitumoral effects, the quantitative value of this response should be interpretable to the antitumoral action, and the timing of the PET scan should be optimized to action of the drug. These conditions are not necessarily known at the start of a drug-development program and need to be explored. We proposed a translational imaging activity in which experiments in spheroids and later in xenografts are coupled to modeling of growth inhibition and to the related changes in the kinetics of PET tracers and other biomarkers. In addition, we demonstrated how this information can be used for planning clinical trials. METHODS: The first part of this concept is illustrated in a spheroid model with BT474 breast cancer cells treated with the heat shock protein 90 (Hsp90) inhibitor NVP-AUY922. The growth-inhibitory effect after a pulse treatment with the drug was measured with digital image analysis to determine effects on volume with high accuracy. The growth-inhibitory effect was described mathematically by a combined E(max) and time course model fitted to the data. The model was then used to simulate a once-per-week treatment; in these experiments the uptake of the PET tracers (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) was determined at different doses and different time points. RESULTS: A drug exposure of 2 h followed by washout of the drug from the culture medium generated growth inhibition that was maximal at the earliest time point of 1 d and decreased exponentially with time during 10-12 d. The uptake of (18)F-FDG per viable tumor volume was minimally affected by the treatment, whereas the (18)F-FLT uptake decreased in correlation with the growth inhibition. CONCLUSION: The study suggests a prolonged action of the Hsp90 inhibitor that supports a once-per-week schedule. (18)F-FLT is a suitable tracer for the monitoring of effect, and the (18)F-FLT PET study might be performed within 3 d after dosing. 相似文献
77.
78.
79.
80.